Skip to main content
Log in

Clinical Pharmacokinetics of Nicotine

  • Review Article
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Summary

Nicotine intake is considered to be a major factor in sustaining tobacco addiction. For this reason, nicotine gum has recently been introduced as an adjuvant to smoking cessation. The introduction of nicotine as a ‘therapeutic’ entity necessitates a careful examination of its clinical pharmacokinetics.

Insufficient data exist to quantitatively assess the absorption of nicotine after oral administration. Based upon physicochemical and pharmacokinetic principles, the oral bioavailability of nicotine would be expected to be less than 20%. The limited data available in the literature appear to support this conclusion. Absorption from the oral mucosa is the principal site of nicotine absorption in subjects who chew tobacco or nicotine gum. Absorption by this route is highly pH dependent. Nicotine is also readily absorbed from the nasal mucosa, and after topical administration.

Nicotine distributes extensively into body tissues with a volume of distribution ranging from 1.0 to 3.0 L/kg. Nicotine has been shown to transfer across the placenta and into breast milk in humans. Plasma protein binding is negligible, ranging from 4.9 to 20%.

The predominant route of nicotine elimination is hepatic metabolism. Although a number of metabolites of nicotine have been identified, it is unclear whether any of these compounds contribute to the pharmacological effect of nicotine. Nicotine is also excreted unchanged in urine in a pH-dependent fashion. With urinary pH less than 5, an average 23% of the nicotine dose is excreted unchanged. When urinary pH is maintained above 7.0, unchanged nicotine urinary excretion drops to 2%.

After intravenous administration, nicotine exhibits biexponential decline in plasma. Total plasma clearance ranges from 0.92 to 2.43 L/min. During urinary acidification, renal clearance averages 0.20 L/min. Non-renal blood clearance averages 1.2 L/min, indicating that nicotine elimination is dependent on hepatic blood flow.

The literature is devoid of information regarding the effect of disease on the pharmacokinetics of nicotine. Based upon the drug’s pharmacokinetics in healthy smokers, it would be anticipated that disease states which alter hepatic blood flow may have the greatest impact on nicotine pharmacokinetics. In addition, drugs which alter hepatic blood flow may cause significant alterations in the systemic clearance of nicotine.

Dependence on smoking appears to be related, at least in part, to the achievement of a rapid rise in plasma nicotine concentrations. If this assessment is correct, the most desirable adjuvant for smoking cessation would be one that closely mimics this pattern of plasma nicotine concentrations. Thus, the slow rise in plasma concentrations after chewing nicotine gum may suggest a pharmacokinetic explanation for the relatively high failure rate with this method of smoking cessation. It appears that because the rate of nicotine absorption is even slower than with the gum formulation, transdermal preparations are unlikely to be a satisfactory alternative to smoking. Further investigations are, therefore,equired to determine a formulation which gives the desired plasma nicotine concentration profile.

One of the major effects of smoking on drug therapy is the induction of drug-metabolising enzymes. However, the effects on drug metabolising capacity when a subject changes from smoking to nicotine gum has not yet been studied. The effect nicotine itself has on drug metabolism in humans is also unknown.

Considerable work remains to define adequately the clinical pharmacokinetics of nicotine. Determination of factors which influence the efficacy of nicotine as an adjuvant in smoking cessation may prove beneficial in reducing the number of tobacco consumers worldwide.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Abel EL. Smoking and pregnancy. Journal of Psychoactive Drugs 16: 327–338, 1984

    Article  PubMed  CAS  Google Scholar 

  • Beckett AH, Gorrod JW, Jenner P. The effect of smoking on nicotine metabolism in vivo in man. Journal of Pharmacy and Pharmacology 23: 62S–67S, 1971

    Article  PubMed  CAS  Google Scholar 

  • Beckett AH, Gorrod JW, Jenner P. A possible relation between pKa and lipid solubility and the amounts excreted in urine of some tobacco alkaloids given to man. Journal of Pharmacy and Pharmacology 24: 115–120, 1972

    Article  PubMed  CAS  Google Scholar 

  • Beckett AH, Triggs EJ. Enzyme induction in man caused by smoking. Nature 216: 587, 1967

    Article  PubMed  CAS  Google Scholar 

  • Benowitz NL. Clinical pharmacology of nicotine. Annual Review of Medicine 37: 21–32, 1986

    Article  PubMed  CAS  Google Scholar 

  • Benowitz NL, Hall SM, Herning RI, Jacob P, Jones RT, et al. Smokers of low-yield cigarettes do not consume less nicotine. New England Journal of Medicine 309: 139–142, 1983

    Article  PubMed  CAS  Google Scholar 

  • Benowitz NL, Jacob P. Nicotine renal excretion rate influences nicotine intake during cigarette smoking. Journal of Pharmacology and Experimental Therapeutics 234: 153–155, 1985

    PubMed  CAS  Google Scholar 

  • Benowitz NL, Jacob P, Jones RT, Rosenberg J. Interindividual variability in the metabolism and cardiovascular effects of nicotine in man. Journal of Pharmacology and Experimental Therapeutics 221: 368–372, 1982

    PubMed  CAS  Google Scholar 

  • Benowitz NL, Kuyt F, Jacob P, Jones RT, Osman A-L. Cotinine disposition and effects. Clinical Pharmacology and Therapeutics 34: 604–611, 1983

    Article  PubMed  CAS  Google Scholar 

  • de Boer AG, Moolenaar F, de Leede LGJ, Breimer DD. Rectal drug administration: clinical pharmacokinetic considerations. Clinical Pharmacokinetics 7: 285–311, 1982

    Article  PubMed  Google Scholar 

  • Daneshmend TK, Jackson L, Roberts CJC. Physiological and pharmacological variability in estimated hepatic blood flow in man. British Journal of Clinical Pharmacology 11: 491–496, 1981

    Article  PubMed  CAS  Google Scholar 

  • Darby TD, McNamee JE, van Rossum JM. Cigarette smoking pharmacokinetics and its relationship to smoking behaviour. Clinical Pharmacokinetics 9: 435–449, 1984

    Article  PubMed  CAS  Google Scholar 

  • Dawson GW, Vestal RE. Smoking and drug metabolism. Pharmacology and Therapeutics 15: 207–221, 1982

    Article  Google Scholar 

  • Department of Health and Human Services. The health consequences of smoking: cardiovascular disease. A report of the Surgeon-General, Rockville, 1983

    Google Scholar 

  • Faulkner JM. Nicotine poisoning by absorption through the skin. Journal of the American Medical Association 100: 1664–1665, 1933

    Article  Google Scholar 

  • Fee WM, Stewart MJ. A controlled trial of nicotine chewing gum in a smoking withdrawal clinic. Practitioner 226: 148–151, 1982

    PubMed  CAS  Google Scholar 

  • Feely J. Nifedipine increases and glyceryl trinitrate decreases apparent liver blood flow in normal subjects. British Journal of Clinical Pharmacology 17: 83–85, 1984

    Article  PubMed  CAS  Google Scholar 

  • Feely J, Wade D, McAllister CB, Wilkinson GR, Robertson D. Effect of hypotension on liver blood flow and lidocaine disposition. New England Journal of Medicine 307: 866–869, 1982

    Article  PubMed  CAS  Google Scholar 

  • Ferno O, Lichtneckert SJA, Lundgren CEG. A substitute for tobacco smoking. Psychopharmacologia 31: 201–204, 1973

    Article  PubMed  CAS  Google Scholar 

  • Feyerabend C, Ings AMJ, Russell MAH. Nicotine pharmacokinetics and its application to intake from smoking. British Journal of Clinical Pharmacology 19: 239–247, 1985

    Article  PubMed  CAS  Google Scholar 

  • Feyerabend C, Russell MAH. Effect of urinary pH and nicotine excretion rate on plasma nicotine during cigarette smoking and chewing nicotine gum. British Journal of Clinical Pharmacology 5: 293–297, 1978

    Article  CAS  Google Scholar 

  • Garcia-Estrada H, Fischman CM. An unusual case of nicotine poisoning. Clinical Toxicology 10: 391–393, 1977

    Article  PubMed  CAS  Google Scholar 

  • Gehlbach SH, Williams WA, Freeman JI. Protective clothing as a means of reducing nicotine absorption in tobacco harvesters. Archives of Environmental Health (March/April): 111–114, 1979

    Google Scholar 

  • Gehlbach SH, Williams WA, Perry LD, Woodhall JS. Green tobacco sickness: an illness of tobacco harvesters. Journal of the American Medical Association 229: 1880–1883, 1974

    Article  PubMed  CAS  Google Scholar 

  • Gorrod JW, Jenner P. The metabolism of tobacco alkaloids. Essays in Toxicology 6: 35–78, 1975

    CAS  Google Scholar 

  • Hassan S, Pickles H. Epoprostenol (prostacyclin, PGI2) increases apparent liver blood flow. British Journal of Clinical Pharmacology 14: 572P, 1982

    Google Scholar 

  • Hisaoka M, Levy G. Kinetics of drug action in disease states XI: effect of nicotine on the pharmacodynamics and pharmacokinetics of phenobarbital and ethanol in rats. Journal of Pharmaceutical Sciences 74: 412–415, 1985

    Article  PubMed  CAS  Google Scholar 

  • Hjalmarson AIM. Effect of nicotine chewing gum in smoking cessation. Journal of the American Medical Association 252: 2835–2838, 1984

    Article  PubMed  CAS  Google Scholar 

  • Hughes JR, Miller SA. Nicotine gum to help stop smoking. Journal of the American Medical Association 252: 2855–2858, 1984

    Article  PubMed  CAS  Google Scholar 

  • Hunt SN, Jusko WJ, Yurchak AM. Effect of smoking on theophylline disposition. Clinical Pharmacology and Therapeutics 19: 546–551, 1976

    PubMed  CAS  Google Scholar 

  • Iserson KV. Caffeine and nicotine. In Haddad & Winchester (Eds) Clinical management of poisoning and drug overdose, pp. 509–515, WB Saunders. Philadelphia, 1983

    Google Scholar 

  • Jarvis MJ, Raw M, Russell MAH, Feyerabend C. Randomised controlled trial of nicotine chewing-gum. British Medical Journal 285: 537–540, 1982

    Article  PubMed  CAS  Google Scholar 

  • Jusko WJ. Role of tobacco smoking in pharmacokinetics. Journal of Pharmacokinetics and Biopharmaceutics 6: 7–39, 1978

    PubMed  CAS  Google Scholar 

  • Kaur S, Ali B. Stimulation of drug and carcinogen metabolism by prolonged oral tobacco consumption. Biochemical Pharmacology 31: 1595–1597, 1982

    Article  PubMed  CAS  Google Scholar 

  • Kim KS, Borzelleca JF, Bowman ER, McKennis H. Effects of some nicotine metabolites and related compounds on isolated smooth muscle. Journal of Pharmacology and Experimental Therapeutics 161: 59–69, 1968

    PubMed  CAS  Google Scholar 

  • Kyerematen GA, Damiano MD, Dvorchik BH, Vesell ES. Smoking-induced changes in nicotine disposition: application of a new HPLC assay for nicotine and its metabolites. Clinical Pharmacology and Therapeutics 32: 769–780, 1982

    Article  PubMed  CAS  Google Scholar 

  • Lang WJ. Factors influencing the self-administration of nicotine and other drugs by rats. Proceedings of the Australian Physiological and Pharmacological Society 11: 33–36, 1980

    CAS  Google Scholar 

  • Leier CV, Patrick TJ, Hermiller J, et al. Nifedipine in congestive heart failure: Effects on resting and exercise hemodynamics and regional blood flow. American Heart Journal 108: 1461–1468, 1984

    Article  PubMed  CAS  Google Scholar 

  • Luck W, Nau H. Exposure to the fetus, neonate, and nursed infant to nicotine and cotinine from maternal smoking. New England Journal of Medicine 311: 672, 1984a

    Article  PubMed  CAS  Google Scholar 

  • Luck W, Nau H. Nicotine and cotinine concentrations in serum and milk of nursing smokers. British Journal of Clinical Pharmacology 18: 9–15, 1984b

    Article  PubMed  CAS  Google Scholar 

  • Malizia E, Andreucci G, Alfani F, Smeriglio M, Nicholai P. Acute intoxication with nicotine alkaloids and cannabinoids in children from ingestion of cigarettes. Human Toxicology 2: 315–316, 1983

    Article  PubMed  CAS  Google Scholar 

  • McNabb ME. Chewing nicotine gum for 3 months: What happens to plasma nicotine levels? Canadian Medical Association Journal 131: 589–592, 1984

    PubMed  CAS  Google Scholar 

  • McNabb ME, Ebert RV, McCusker K. Plasma nicotine levels produced by chewing nicotine gum. Journal of the American Medical Association 248: 865–868, 1982

    Article  PubMed  CAS  Google Scholar 

  • Meredith PA, Pasanisi F, Elliott HL, Reid JL. The effect of nisoldipine on apparent liver blood flow and effective renal plasma flow. British Journal of Clinical Pharmacology 20: 235–237, 1985

    Article  PubMed  CAS  Google Scholar 

  • Miller RP, Rotenberg KS, Adir J. Effect of dose on the pharmacokinetics of intravenous nicotine in the rat. Drug Metabolism and Disposition 5: 436–443, 1977

    PubMed  CAS  Google Scholar 

  • Parker G, Ene MD, Daneshmend TK, Roberts CJC. Effects of nadolol, propranolol and metoprolol on the clearances of indocyanine green and antipyrine in man. British Journal of Clinical Pharmacology 15: 610P, 1983

    Google Scholar 

  • Roberts CJC, Jackson L, Halliwell M, Branch RA. The relationship between liver volume, antipyrine clearance and indocyanine green clearance before and after phenobarbitone administration in man. British Journal of Clinical Pharmacology 3: 907–913, 1976

    Article  PubMed  CAS  Google Scholar 

  • Rose JE, Herskovic JE, Trilling Y, Jarvik ME. Transdermal nicotine reduces cigarette craving and nicotine preference. Clinical Pharmacology and Therapeutics 38: 450–456, 1985

    Article  PubMed  CAS  Google Scholar 

  • Rose JE, Jarvik ME, Rose KD. Transdermal administration of nicotine. Drug and Alcohol Dependence 13: 209–213, 1984

    Article  PubMed  CAS  Google Scholar 

  • Rosenberg J, Benowitz NL, Jacob P, Wilson KM. Disposition kinetics and effects of intravenous nicotine. Clinical Pharmacology and Therapeutics 28: 517–522, 1980

    Article  PubMed  CAS  Google Scholar 

  • Ruddon RW, Cohen AM. Alteration of enzyme activity in rat liver following the acute and chronic administration of nicotine. Toxicology and Applied Pharmacology 16: 613–625, 1970

    Article  PubMed  CAS  Google Scholar 

  • Russell MAH, Feyerabend C. Cigarette smoking: A dependence on high-nicotine boli. Drug Metabolism Reviews 8: 29–57, 1978

    Article  PubMed  CAS  Google Scholar 

  • Russell MAH, Jarvis MJ, Devitt G, Feyerabend C. Nicotine intake by snuff users. British Medical Journal 283: 814–817, 1981

    Article  PubMed  CAS  Google Scholar 

  • Russell MAH, Jarvis MJ, Feyerabend C. A new age for snuff? Lancet 1: 474–475, 1980

    Article  PubMed  CAS  Google Scholar 

  • Russell MAH, Jarvis MJ, Feyerabend C, Ferno O. Nasal nicotine solution: a potential aid to giving up smoking? British Medical Journal 286: 683–684, 1983

    Article  PubMed  CAS  Google Scholar 

  • Russell MAH, Raw M, Jarvis MJ. Clinical use of nicotine-chewing gum. British Medical Journal 280: 1599–1602, 1980

    Article  PubMed  CAS  Google Scholar 

  • Schievelbein H. Nicotine, resorption and fate. In Balfour (Ed.) Nicotine and the smoking habit, pp. 1–15, Pergamon Press, Oxford, 1984

    Google Scholar 

  • Schmiterlow CG, Hansson E, Andersson G, Appelgren L-E, Hoffmann PC. Distribution of nicotine in the central nervous system. Annals of the New York Academy of Science 142: 2–14, 1967

    Article  CAS  Google Scholar 

  • Stalhandske T. Effects of increased liver metabolism of nicotine on its uptake, elimination and toxicity in mice. Acta Physiologica Scandinavica 80: 222–234, 1970

    Article  PubMed  CAS  Google Scholar 

  • Svensson CK, Cumella JC, Tronolone M, Middleton Jr E, Lalka D. Effects of hydralazine, nitroglycerin and food on estimated hepatic blood flow. Clinical Pharmacology and Therapeutics 37: 464–468, 1985

    Article  PubMed  CAS  Google Scholar 

  • Svensson CK, Edwards DJ, Mauriello PM, Barde SH, Foster AC, et al. Effect of food on hepatic blood flow: Implications in the food effect phenomenon. Clinical Pharmacology and Therapeutics 34: 316–323, 1983

    Article  PubMed  CAS  Google Scholar 

  • Temple DJ. The absorption of nicotine from tobacco snuff through the nasal mucosa. Archives of Pharmacology 12: 984–987, 1976

    Google Scholar 

  • Travell J. The influence of the hydrogen ion concentration on the absorption of alkaloids from the stomach. Journal of Pharmacology and Experimental Therapeutics 69: 21–33, 1940

    CAS  Google Scholar 

  • Travell J. Absorption of nicotine from various sites. Annals New York Academy of Sciences 90: 13–30, 1960

    Article  CAS  Google Scholar 

  • Tsujimoto A, Nakashima T, Tanino S, Dohi T, Kurogochi Y. Tissue distribution of [3H] nicotine in dogs and rhesus monkeys. Toxicology and Applied Pharmacology 32: 21–31, 1975

    Article  PubMed  CAS  Google Scholar 

  • Vestal RE, Wood AJJ, Branch RA, Shand DG, Wilkinson GR. Effects of age and cigarette smoking on propranolol disposition. Clinical Pharmacology and Therapeutics 26: 8–15, 1979

    PubMed  CAS  Google Scholar 

  • Wells PG, Feely J, Wilkinson GR, Wood AJJ. Effect of thyrotoxicosis on liver blood flow and propranolol disposition after long-term dosing. Clinical Pharmacology and Therapeutics 33: 603–608, 1983

    Article  PubMed  CAS  Google Scholar 

  • Wenzel DG, Broadie LL. Stimulatory effect of nicotine on the metabolism of meprobamate. Toxicology and Applied Pharmacology 8: 455–459, 1966

    Article  PubMed  CAS  Google Scholar 

  • West RJ, Jarvis MJ, Russell MAH, Feyerabend C. Plasma nicotine concentrations from repeated doses of nasal nicotine solution. British Journal of Addiction 79: 443–445, 1984

    Article  PubMed  CAS  Google Scholar 

  • Wilkinson GR, Shand DG. A physiological approach to hepatic drug clearance. Clinical Pharmacology and Therapeutics 18: 377–390, 1975

    PubMed  CAS  Google Scholar 

  • Williams RL, Blaschke TF, Meffin PJ, Melmon KL, Rowland M. Influence of viral hepatitis on the disposition of two compounds with high hepatic clearance: lidocaine and indocyanine green. Clinical Pharmacology and Therapeutics 20: 290–299, 1976

    PubMed  CAS  Google Scholar 

  • Willis HW. Acute nicotine poisoning. Journal of Pediatrics 10: 65–68, 1937

    Article  Google Scholar 

  • Wood AJJ, Kornhauser DM, Wilkinson GR, Shand DG, Branch RA. The influence of cirrhosis on steady-state blood concentrations of unbound propranolol after oral administration. Clinical Pharmacokinetics 3: 478–487, 1978

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Svensson, C.K. Clinical Pharmacokinetics of Nicotine. Clin-Pharmacokinet 12, 30–40 (1987). https://doi.org/10.2165/00003088-198712010-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-198712010-00003

Keywords

Navigation